January 7, 2016 Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer Breakthroughs 2020 Program Nation’s first insurance coverage of next generation whole genome sequencing and proteomic...
SEATTLE (August 5, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced an average survival increase of 11 months in end-stage colorectal cancer patients in Cancer Immunology,...
